Brokerages Set Inovio Pharmaceuticals Inc (INO) Target Price at $12.17
June 10th, 2018 - By Gary James
 Shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) have received an average recommendation of “Buy” from the nine research firms that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $12.17.
INO has been the subject of a number of analyst reports. Maxim Group cut their price objective on shares of Inovio Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, February 15th. BidaskClub raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, March 14th. ValuEngine upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, May 11th. HC Wainwright set a $13.00 target price on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, May 10th. Finally, Royal Bank of Canada boosted their target price on shares of Inovio Pharmaceuticals from $11.00 to $14.00 and gave the company an “outperform” rating in a report on Thursday, March 15th.
In other Inovio Pharmaceuticals news, CEO Jong Joseph Kim sold 103,750 shares of the business’s stock in a transaction that occurred on Thursday, April 12th. The shares were sold at an average price of $5.14, for a total transaction of $533,275.00. Following the completion of the sale, the chief executive officer now directly owns 2,395,557 shares in the company, valued at $12,313,162.98. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director David B. Weiner sold 9,000 shares of the business’s stock in a transaction that occurred on Monday, April 16th. The stock was sold at an average price of $4.91, for a total transaction of $44,190.00. Following the sale, the director now owns 758,956 shares of the company’s stock, valued at $3,726,473.96. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 116,500 shares of company stock valued at $597,078. 9.40% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in INO. Guggenheim Capital LLC purchased a new stake in Inovio Pharmaceuticals during the first quarter worth approximately $2,375,000. Renaissance Technologies LLC purchased a new stake in Inovio Pharmaceuticals during the fourth quarter worth approximately $1,503,000. Deutsche Bank AG grew its stake in Inovio Pharmaceuticals by 247.7% during the fourth quarter. Deutsche Bank AG now owns 449,708 shares of the biopharmaceutical company’s stock worth $1,856,000 after buying an additional 320,376 shares during the period. UBS Group AG grew its stake in Inovio Pharmaceuticals by 156.7% during the first quarter. UBS Group AG now owns 442,893 shares of the biopharmaceutical company’s stock worth $2,086,000 after buying an additional 270,373 shares during the period. Finally, ARK Investment Management LLC grew its stake in Inovio Pharmaceuticals by 99.7% during the fourth quarter. ARK Investment Management LLC now owns 286,277 shares of the biopharmaceutical company’s stock worth $1,182,000 after buying an additional 142,894 shares during the period. Institutional investors own 32.82% of the company’s stock. Shares of Inovio Pharmaceuticals traded down $0.11, reaching $4.65, during trading on Thursday, Marketbeat.com reports. The stock had a trading volume of 860,220 shares, compared to its average volume of 1,198,817. The firm has a market cap of $425.70 million, a PE ratio of -4.27 and a beta of 2.52. Inovio Pharmaceuticals has a fifty-two week low of $3.76 and a fifty-two week high of $8.64.
Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Wednesday, May 9th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.22). The firm had revenue of $1.53 million during the quarter, compared to analyst estimates of $7.50 million. Inovio Pharmaceuticals had a negative net margin of 292.06% and a negative return on equity of 72.04%. During the same period in the prior year, the firm earned ($0.31) EPS. equities analysts expect that Inovio Pharmaceuticals will post -1.36 earnings per share for the current year.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
mareainformativa.com |
